Metastatic CDK12-Mutated Neuroendocrine Tumor of Lung Showed an Exceptional Response to Olaparib and Paclitaxel

JCO Precis Oncol. 2021 Nov:5:751-755. doi: 10.1200/PO.20.00400.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Cyclin-Dependent Kinases / genetics
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Male
  • Mutation
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / genetics
  • Neuroendocrine Tumors / secondary
  • Paclitaxel / therapeutic use*
  • Phthalazines / therapeutic use*
  • Piperazines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Phthalazines
  • Piperazines
  • CDK12 protein, human
  • Cyclin-Dependent Kinases
  • Paclitaxel
  • olaparib